Quadratus Lumborum Block for Abdominoplasty

• Status: Completed
• Trial end date: 2017-12-13
• Target enrollment: 0
• Participant gender: All

Summary

Double blinded, randomized, controlled, phase IV intervention trial. Both groups will receive a quadratus lumborum Block (QL), using ropivacaine 3.75 mg/mL in the intervention group, and sterile sodium chloride in the control group. The aim of study is to investigate the effect of a QL Block on the perioperative pain during postbariatric abdominoplasty.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vestre Viken Hospital Trust
• Treatments: Ropivacaine

Criteria

Inclusion Criteria:

• American Society of Anesthesiologists Physical Classification Status (ASA) I-II

• Age 18 to 64

• Weight above or equal to 60 kg

• Scheduled for post-bariatric surgery with standard full abdominoplasty performed by Dr Frøyen

• Patient is expected able to cooperate during the treatment and follow up.

• Signed informed consent obtained and documented according to the International Conference on Harmonization (ICH) good clinical practice (GCP), and national/local regulations.

Exclusion Criteria:

• A history of anaphylactic shock

• Cardiovascular disease other than hypertension and/or hyperlipidemia

• Known allergy to ropivacaine or morphine

• A history of chronic pain

• Psychiatric comorbidity

• Scheduled opioid pain medication or neuroleptic drugs

• Coagulation disorders or treatment with platelet inhibitors

• Pregnancy or breastfeeding

• Treatment with class III antiarrhythmics, sertindole, ziprasidone, amisulpride, ceritinib, hydroxyzine, fluvoxamine

• Any medical contraindication to the study intervention by the attending anaesthetist or surgeon (to be specified in screening form).